Future studies should aim to validate this hypothesis by assessing the active forms of IL-36, IL-37, and IL-38 both in serum and, crucially, within lesional tissue, to better characterize their local biological activity in pyoderma gangrenosum. This evidence concerns the gene IL1F10 and pyoderma gangrenosum.